Genfit S.A. (GNFT)
NASDAQ: GNFT · Real-Time Price · USD
5.35
+0.06 (1.13%)
Oct 3, 2024, 12:43 PM EDT - Market open
Genfit Employees
Genfit had 159 employees as of December 31, 2023. The number of employees increased by 11 or 7.43% compared to the previous year.
Employees
159
Change (1Y)
11
Growth (1Y)
7.43%
Revenue / Employee
$542,297
Profits / Employee
$150,079
Market Cap
264.85M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Amarin Corporation | 275 |
Biodesix | 217 |
TScan Therapeutics | 154 |
Zentalis Pharmaceuticals | 124 |
Sanara MedTech | 108 |
Solid Biosciences | 88 |
Rezolute | 51 |
ESSA Pharma | 50 |
GNFT News
- 9 days ago - Top 4 Health Care Stocks That May Keep You Up At Night - Benzinga
- 10 days ago - GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval - GlobeNewsWire
- 2 months ago - GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis - GlobeNewsWire
- 3 months ago - GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewsWire
- 3 months ago - GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH - GlobeNewsWire
- 4 months ago - GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis - GlobeNewsWire
- 4 months ago - US FDA approves Genfit and Ipsen's liver disease drug - Reuters
- 4 months ago - GENFIT to Present Latest ACLF Research at EASL Congress™ 2024 - GlobeNewsWire